EVFM•Evofem Biosciences reported third-quarter 2026 net income attributable to common stockholders of $865,000, compared with a year-earlier loss. Net sales fell 7% to $4.63 million, while restricted cash and cash equivalents fell 45% to $317,000.
Evofem Biosciences swung to third-quarter 2026 net income attributable to common stockholders of $865,000 from a year-earlier loss. Net sales fell 7% year over year to $4.63 million, primarily due to lower PHEXX ex-factory sales. Restricted cash and cash equivalents were $317,000 at September 30, 2026, down 45% from December 31, 2025.
The company contracted a second pharmaceutical manufacturer to produce PHEXX, aiming to enhance manufacturing flexibility and reduce costs.
